# Pappas Capital

> Pappas Capital is a Durham, North Carolina venture capital and commercial development firm founded in 1994 by former pharmaceutical executive Art Pappas. It backs and helps build life-science companies, creates tailored investment vehicles for strategic investors, and works with research institutions to move promising inventions toward licensing or company formation. The firm says it has managed more than $800 million, invested in more than 100 companies, and helped portfolio companies develop 27 approved products.

- **Founded:** 1994
- **Headquarters:** Durham, United States
- **Founders:** Art Pappas (Founder and Managing Partner)
- **Team size:** Approximately 32 employees, based on supplied company data; the public team roster also includes venture partners, advisers and scientific board members.
- **Products:** Pappas Ventures, Specialized Fund Management, Pappas Translational Medicine, Specialized Holdings
- **Notable:** More than $800 million managed since inception, according to the firm., More than 100 portfolio companies financed through its business lines., Six flagship Pappas Ventures funds raised.

## Products & services

- **Pappas Ventures** — The flagship venture business invests in and helps build life-science companies from concept through commercialization, with emphasis on novel products for unmet medical needs.
- **Specialized Fund Management** — Customized investment vehicles designed around the strategic objectives of corporate and family-office investors, including market expansion and business development.
- **Pappas Translational Medicine** — Hands-on programs with academic institutions that select, fund and manage research projects toward licensing, outside investment or company formation.
- **Specialized Holdings** — Selective investments of the firm's own capital in companies or third-party funds where its team and industry relationships can affect outcomes.

## Achievements

- More than $800 million managed since inception, according to the firm.
- More than 100 portfolio companies financed through its business lines.
- Six flagship Pappas Ventures funds raised.
- 40 IPO or M&A transactions across the Pappas portfolio, according to the firm.
- Four portfolio companies sold for $1 billion or more, according to the firm.
- Eight companies founded or co-founded by Pappas.
- 27 approved products developed by portfolio companies, according to the firm's current scorecard.

## Latest updates

- **2026-06** — Portfolio company Aura Biosciences announced completion of enrollment in its Phase 3 CoMpass trial.
- **2026-05** — Portfolio company Aktis Oncology reported first-in-human clinical imaging and dosimetry data and continued advancing its targeted radiopharmaceutical pipeline.
- **2026-04** — Horizon Quantum announced a strategic agreement with IonQ, while Glycomine completed enrollment in a global Phase 2b study.
- **2026-01** — Aktis Oncology priced an upsized initial public offering.
- **2025-09** — Enlaza Therapeutics announced a strategic collaboration with Vertex Pharmaceuticals.

## Links

- Website: https://www.pappas-capital.com/
- LinkedIn: https://www.linkedin.com/company/pappas-capital
- Twitter/X: https://www.twitter.com/pappasventures

---

Profile page: https://yespress.io/pappas-capital
Published by YesPress — https://yespress.io
Last updated: 2026-08-17